Skip to main content
Welcome to "The Poster!" To become a subscriber and start getting updates on new content, subscribe now!

In the News

Science & Technology | Dr. Omalu Talks Childhood, Concussions, and CTE

Dr. Bennet Omalu, the famed forensic pathologist who discovered Chronic Traumatic Encephalopathy (CTE), recently spoke at NCI at Frederick about his upbringing as well as the trials he faced while working to educate the NFL about CTE.

Science & Technology | Using High-Powered Laser, Scientists Record Images of Chemical Interactions in RNA

A recent study at the Department of Energy’s Stanford Linear Accelerator Center National Accelerator Laboratory has literally shed new light on the structural interactions between RNA and another biomolecule.

Publications | Platinum Publications, March 31–April 27, 2017

Platinum Publications are selected from articles by NCI at Frederick scientists published in 42 prestigious science journals. This list represents articles published during the time period shown above, as generated from PubMed. Articles designated as Platinum Highlights are noteworthy articles selected from among the most recently published Platinum Publications.

Students | WHK Interns Highlight the Importance of Their Work

The Werner H. Kirsten (WHK) student interns at the National Cancer Institute (NCI) at Frederick are participating in groundbreaking cancer research, along with large-scale projects and technological advancements, during their senior year of high school. The interns at NCI at Frederick are given more than the opportunity to watch the research; they participate in and conduct their own projects to contribute to the NCI mission.

Science & Technology | Large Cancer Drug Trial Helps Move Precision Medicine Toward the Mainstream

A landmark cancer drug trial is helping set the stage for moving precision medicine into the mainstream of clinical practice, according to a new study. The study, reported in the Journal of Molecular Diagnostics, validates a procedure used in the drug trial that identifies the unique genetic mutations in a patient’s tumor, which is then used as the basis for selecting targeted drugs for treatment.